How long does the patent protection for Vimpat last?
“Vimpat” is the brand name for lacosamide. Patent protection in the pharmaceutical market usually runs in layers (drug substance patents, formulation/process patents, and additional periods tied to regulatory exclusivity in the relevant country). The exact end date for “Vimpat-Patentschutz” depends on the jurisdiction (for example Germany/EU vs. US vs. UK) and on which specific patent(s) and exclusivity rules apply in that country.
What does “Patentschutz” mean in practice for lacosamide (Vimpat)?
In practice, market exclusivity can keep generics/biosimilars off the market even after the original patent(s) expire, because additional legal protections may still apply, such as:
- Secondary patents (for example on specific formulations or manufacturing)
- Regulatory exclusivity tied to the approval process (country-specific)
- Patent enforcement (where courts may pause or delay generic launches)
When can generic Vimpat enter after patent expiry?
Generic entry timing is driven by whether companies can obtain marketing authorization and whether there are still:
- active patents that cover the product, and/or
- enforceable exclusivity periods in that country.
So the key “when” question is not just “when does the first patent expire,” but when the last enforceable barrier is removed for that market.
Where is Vimpat patent protection relevant: Germany/EU vs. US?
Patent and exclusivity timelines differ widely by region because:
- EU and national rules (and supplementary protection mechanisms) differ from the US,
- and companies may obtain different patent families in different countries.
If you tell me the country (e.g., Germany / Austria / EU-wide / US / UK) and whether you mean patent expiry or generic launch timing, I can narrow the answer to the relevant legal framework.
How can you check the exact end date for Vimpat patentschutz?
To get a precise date, you need to look up:
- the lacosamide patent family in the relevant jurisdiction,
- the specific patent numbers covering the marketed product,
- and any supplementary protection or regulatory exclusivity that extends market protection.
This is easiest if you provide either:
- your country of interest, or
- the patent list you already found (then I can help interpret which ones matter for market exclusivity).
What if you’re asking because a generic already launched?
If a generic (or “AbbVie/Mylan/Teva/etc.” style competitor in that market) is already sold, that usually means one of these is true for that jurisdiction:
- the relevant patents/exclusivity have already expired, or
- the generic entered via a settlement/authorization path despite still-pending IP (details vary by case and country).
Quick clarification to answer precisely
Which market do you mean by “Vimpat patentschutz”:
1) Germany/EU, 2) US, or 3) another country?
And do you want the exact patent expiry date or the latest possible date for generic entry in that market?